$MGTX
MeiraGTx Holdings plc

2023 Q3 Form 10-Q Financial Statement

#000155837023014416 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $5.103M $3.540M
YoY Change 5.96% -67.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.01M $12.39M
YoY Change -6.99% 17.78%
% of Gross Profit
Research & Development $27.86M $19.94M
YoY Change 65.2% -16.93%
% of Gross Profit
Depreciation & Amortization $3.480M $3.247M
YoY Change 71.6% 55.73%
% of Gross Profit
Operating Expenses $37.87M $32.33M
YoY Change 37.07% -6.35%
Operating Profit -$32.76M -$28.79M
YoY Change 43.64% 21.16%
Interest Expense $3.381M $3.355M
YoY Change 78.7% 3991.46%
% of Operating Profit
Other Income/Expense, Net -$40.00K -$1.000K
YoY Change -46.67% -100.48%
Pretax Income -$44.30M -$29.58M
YoY Change 18.82% -12.93%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$44.30M -$29.58M
YoY Change 18.81% -12.93%
Net Earnings / Revenue -868.06% -835.62%
Basic Earnings Per Share -$0.74 -$0.53
Diluted Earnings Per Share -$0.74 -$0.53
COMMON SHARES
Basic Shares Outstanding 59.54M 59.50M
Diluted Shares Outstanding 59.53M 55.35M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.40M $92.77M
YoY Change -44.73% 28.66%
Cash & Equivalents $63.37M $92.77M
Short-Term Investments
Other Short-Term Assets $758.0K $1.547M
YoY Change -51.44% -53.54%
Inventory
Prepaid Expenses $6.997M $8.108M
Receivables $22.40M $32.69M
Other Receivables $10.00M $8.026M
Total Short-Term Assets $103.5M $143.1M
YoY Change -33.22% 37.1%
LONG-TERM ASSETS
Property, Plant & Equipment $111.9M $114.0M
YoY Change 19.5% 24.75%
Goodwill
YoY Change
Intangibles $1.140M $1.252M
YoY Change -11.83% -15.06%
Long-Term Investments $6.326M $6.326M
YoY Change -4.96% -4.96%
Other Assets $1.421M $1.465M
YoY Change 7.49% -2.66%
Total Long-Term Assets $163.7M $167.1M
YoY Change 11.81% 12.88%
TOTAL ASSETS
Total Short-Term Assets $103.5M $143.1M
Total Long-Term Assets $163.7M $167.1M
Total Assets $267.2M $310.3M
YoY Change -11.35% 22.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.77M $28.50M
YoY Change -4.24% 57.35%
Accrued Expenses $28.25M $24.89M
YoY Change 14.03% 5.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $63.51M $71.80M
YoY Change -12.23% 6.37%
LONG-TERM LIABILITIES
Long-Term Debt $71.80M $71.57M
YoY Change 1.35%
Other Long-Term Liabilities $39.80M $43.17M
YoY Change 12.55% 0.86%
Total Long-Term Liabilities $111.6M $114.7M
YoY Change 5.08% 168.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.51M $71.80M
Total Long-Term Liabilities $111.6M $114.7M
Total Liabilities $175.3M $186.7M
YoY Change -1.92% 69.01%
SHAREHOLDERS EQUITY
Retained Earnings -$574.4M -$530.1M
YoY Change 29.69% 30.7%
Common Stock $2.000K $2.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $91.89M $123.5M
YoY Change
Total Liabilities & Shareholders Equity $267.2M $310.3M
YoY Change -11.35% 22.9%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$44.30M -$29.58M
YoY Change 18.81% -12.93%
Depreciation, Depletion And Amortization $3.480M $3.247M
YoY Change 71.6% 55.73%
Cash From Operating Activities -$24.42M -$29.01M
YoY Change 17.82% 4.33%
INVESTING ACTIVITIES
Capital Expenditures $3.560M $4.975M
YoY Change -135.56% -135.54%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$3.560M -$4.975M
YoY Change -64.44% -64.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -410.0K 57.95M
YoY Change -100.56%
NET CHANGE
Cash From Operating Activities -24.42M -29.01M
Cash From Investing Activities -3.560M -4.975M
Cash From Financing Activities -410.0K 57.95M
Net Change In Cash -28.39M 23.96M
YoY Change -167.26% -157.31%
FREE CASH FLOW
Cash From Operating Activities -$24.42M -$29.01M
Capital Expenditures $3.560M $4.975M
Free Cash Flow -$27.98M -$33.99M
YoY Change 161.13% 146.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55349534
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44668240
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52012382
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44585239
CY2023Q2 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://meiragtx.com/20230630#LeaseObligationsNonCurrent
CY2022Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://meiragtx.com/20230630#LeaseObligationsNonCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001735438
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48477209
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59535314
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38520
dei Entity Registrant Name
EntityRegistrantName
MeiraGTx Holdings plc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1448305
dei Entity Address Address Line1
EntityAddressAddressLine1
450 East 29th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10016
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
860-7985
dei Security12b Title
Security12bTitle
Ordinary Shares,$0.00003881 par value per share
dei Trading Symbol
TradingSymbol
MGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59535314
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92773000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115516000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32690000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21334000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8108000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8133000
CY2023Q2 mgtx Tax Incentive Receivable
TaxIncentiveReceivable
8026000
CY2022Q4 mgtx Tax Incentive Receivable
TaxIncentiveReceivable
7689000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1547000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1667000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
143144000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
154339000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114004000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
109266000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1252000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1335000
CY2023Q2 mgtx In Process Research And Development
InProcessResearchAndDevelopment
753000
CY2022Q4 mgtx In Process Research And Development
InProcessResearchAndDevelopment
742000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1465000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1402000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
6326000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
6326000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18693000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20109000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24626000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24718000
CY2023Q2 us-gaap Assets
Assets
310263000
CY2022Q4 us-gaap Assets
Assets
318237000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
28497000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16616000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24889000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39818000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4126000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3884000
CY2023Q2 mgtx Deferred Revenue Related Party Current
DeferredRevenueRelatedPartyCurrent
12058000
CY2022Q4 mgtx Deferred Revenue Related Party Current
DeferredRevenueRelatedPartyCurrent
15123000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2233000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6631000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
71803000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82072000
CY2023Q2 mgtx Deferred Revenue Related Party Noncurrent
DeferredRevenueRelatedPartyNoncurrent
25364000
CY2022Q4 mgtx Deferred Revenue Related Party Noncurrent
DeferredRevenueRelatedPartyNoncurrent
27436000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15508000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17331000
CY2023Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2301000
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2179000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
189000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
186000
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
71571000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
71033000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
262000
CY2023Q2 us-gaap Liabilities
Liabilities
186736000
CY2022Q4 us-gaap Liabilities
Liabilities
200499000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00003881
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00003881
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1288327750
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1288327750
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59535314
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48477209
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
652521000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
581893000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1153000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6047000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-530149000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-470204000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
123527000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117738000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
310263000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
318237000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3540000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10759000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6874000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16392000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12388000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10518000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25160000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21786000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19937000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23999000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42259000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47098000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
32325000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
34517000
us-gaap Operating Expenses
OperatingExpenses
67419000
us-gaap Operating Expenses
OperatingExpenses
68884000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28785000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23758000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60545000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52492000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1905000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10426000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
5762000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13073000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
655000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
41000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1200000
us-gaap Investment Income Interest
InvestmentIncomeInterest
57000
CY2023Q2 us-gaap Interest Expense
InterestExpense
3355000
CY2022Q2 us-gaap Interest Expense
InterestExpense
82000
us-gaap Interest Expense
InterestExpense
6415000
us-gaap Interest Expense
InterestExpense
159000
CY2023Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-1000
CY2022Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
252000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
53000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
649000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29581000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-33973000
us-gaap Net Income Loss
NetIncomeLoss
-59945000
us-gaap Net Income Loss
NetIncomeLoss
-65018000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2541000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7357000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4894000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
9290000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32122000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26616000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64839000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55728000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29581000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33973000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59945000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-65018000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55349534
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44668240
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52012382
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44585239
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117738000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5201000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2353000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30364000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
90222000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7271000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57947000
CY2023Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
209000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2541000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29581000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
123527000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185401000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4996000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1933000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31045000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
161285000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7303000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7357000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-33973000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
141972000
us-gaap Profit Loss
ProfitLoss
-59945000
us-gaap Profit Loss
ProfitLoss
-65018000
us-gaap Share Based Compensation
ShareBasedCompensation
13703000
us-gaap Share Based Compensation
ShareBasedCompensation
14881000
mgtx Cash Flow Effect On Foreign Currency Loss
CashFlowEffectOnForeignCurrencyLoss
-5762000
mgtx Cash Flow Effect On Foreign Currency Loss
CashFlowEffectOnForeignCurrencyLoss
13073000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6339000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4203000
mgtx Cash Flow Effect Of Changes In Right Of Use Assets And Liabilities
CashFlowEffectOfChangesInRightOfUseAssetsAndLiabilities
-104000
mgtx Cash Flow Effect Of Changes In Right Of Use Assets And Liabilities
CashFlowEffectOfChangesInRightOfUseAssetsAndLiabilities
-98000
mgtx Amortization Of Interest On Asset Retirement Obligation
AmortizationOfInterestOnAssetRetirementObligation
89000
mgtx Amortization Of Interest On Asset Retirement Obligation
AmortizationOfInterestOnAssetRetirementObligation
84000
mgtx Amortization Of Debt Discount
AmortizationOfDebtDiscount
538000
mgtx Cash Flow Effect On Fair Value Adjustment Of Acquisition Liability
CashFlowEffectOnFairValueAdjustmentOfAcquisitionLiability
-53000
mgtx Cash Flow Effect On Fair Value Adjustment Of Acquisition Liability
CashFlowEffectOnFairValueAdjustmentOfAcquisitionLiability
-649000
mgtx Decrease Increase In Related Party Accounts Receivable
DecreaseIncreaseInRelatedPartyAccountsReceivable
-10552000
mgtx Decrease Increase In Related Party Accounts Receivable
DecreaseIncreaseInRelatedPartyAccountsReceivable
5794000
mgtx Decrease Increase In Prepaid Expenses
DecreaseIncreaseInPrepaidExpenses
198000
mgtx Decrease Increase In Prepaid Expenses
DecreaseIncreaseInPrepaidExpenses
1009000
mgtx Decrease Increase In Tax Incentive Receivable
DecreaseIncreaseInTaxIncentiveReceivable
5565000
mgtx Decrease Increase In Other Current Assets
DecreaseIncreaseInOtherCurrentAssets
196000
mgtx Decrease Increase In Other Current Assets
DecreaseIncreaseInOtherCurrentAssets
-1096000
mgtx Decrease Increase In Other Assets
DecreaseIncreaseInOtherAssets
-15000
mgtx Decrease Increase In Other Assets
DecreaseIncreaseInOtherAssets
-109000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13072000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3706000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-17234000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1058000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6874000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-16392000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66404000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36105000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13580000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
26460000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13580000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26460000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
192000
mgtx Adjustments To Additional Paid In Capital Taxes Withheld On Issuance Of Share Based Awards
AdjustmentsToAdditionalPaidInCapitalTaxesWithheldOnIssuanceOfShareBasedAwards
-1231000
mgtx Adjustments To Additional Paid In Capital Taxes Withheld On Issuance Of Share Based Awards
AdjustmentsToAdditionalPaidInCapitalTaxesWithheldOnIssuanceOfShareBasedAwards
-2774000
mgtx Proceeds From Issuance Of Ordinary Shares
ProceedsFromIssuanceOfOrdinaryShares
61950000
mgtx Issuance Costs In Connection With Ordinary Shares
IssuanceCostsInConnectionWithOrdinaryShares
-4003000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56716000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2582000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-23268000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-65147000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
525000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-448000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115516000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
137703000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92773000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72108000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
2385000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
7484000
mgtx Right Of Use Assets Obtained In Exchange For Lease Liabilities
RightOfUseAssetsObtainedInExchangeForLeaseLiabilities
1793000
mgtx Asset Retirement Obligations Incurred In Connection With Leases Non Cash
AssetRetirementObligationsIncurredInConnectionWithLeasesNonCash
9000
mgtx Issuance Of Shares In Connection With Asset Acquisition Non Cash
IssuanceOfSharesInConnectionWithAssetAcquisitionNonCash
209000
us-gaap Interest Paid Net
InterestPaidNet
6989000
us-gaap Interest Paid Net
InterestPaidNet
75000
mgtx No.Of Programs In Clinical Development
No.OfProgramsInClinicalDevelopment
6
mgtx No.Of Distinct Areas Of Unmet Medical Need
No.OfDistinctAreasOfUnmetMedicalNeed
3
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-530100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66400000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 24.45pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.45pt;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, the accounting for research and development costs, share-based compensation, valuation of warrants, leases, asset retirement obligations and tax incentive receivable.</p>
CY2022Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2179000
CY2021Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2081000
us-gaap Asset Retirement Obligation Liabilities Incurred
AssetRetirementObligationLiabilitiesIncurred
9000
mgtx Amortization Of Interest On Asset Retirement Obligation
AmortizationOfInterestOnAssetRetirementObligation
89000
mgtx Amortization Of Interest On Asset Retirement Obligation
AmortizationOfInterestOnAssetRetirementObligation
84000
us-gaap Asset Retirement Obligation Foreign Currency Translation Gain Loss
AssetRetirementObligationForeignCurrencyTranslationGainLoss
33000
us-gaap Asset Retirement Obligation Foreign Currency Translation Gain Loss
AssetRetirementObligationForeignCurrencyTranslationGainLoss
-75000
CY2023Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2301000
CY2022Q2 us-gaap Asset Retirement Obligation
AssetRetirementObligation
2099000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11808174
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9244830
CY2023Q2 us-gaap Noncurrent Assets
NoncurrentAssets
167119000
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
163898000
CY2023Q2 us-gaap Equity Method Investment Quoted Market Value
EquityMethodInvestmentQuotedMarketValue
6326000
CY2023Q2 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
6665000
CY2023Q2 mgtx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
11593000
CY2022Q4 mgtx Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
13041000
CY2023Q2 mgtx Accrued Research And Development
AccruedResearchAndDevelopment
4970000
CY2022Q4 mgtx Accrued Research And Development
AccruedResearchAndDevelopment
7400000
CY2023Q2 mgtx Accrued Liabilities Accrued Compensation And Benefits
AccruedLiabilitiesAccruedCompensationAndBenefits
2527000
CY2022Q4 mgtx Accrued Liabilities Accrued Compensation And Benefits
AccruedLiabilitiesAccruedCompensationAndBenefits
732000
CY2023Q2 mgtx Accrued Liabilities Accrued Manufacturing Costs Expense
AccruedLiabilitiesAccruedManufacturingCostsExpense
2537000
CY2022Q4 mgtx Accrued Liabilities Accrued Manufacturing Costs Expense
AccruedLiabilitiesAccruedManufacturingCostsExpense
4326000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1440000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9600000
CY2023Q2 mgtx Accrued Consulting Expenses
AccruedConsultingExpenses
1176000
CY2022Q4 mgtx Accrued Consulting Expenses
AccruedConsultingExpenses
694000
CY2023Q2 mgtx Accrued Expenses Incurred In Connection With Fixed Assets
AccruedExpensesIncurredInConnectionWithFixedAssets
386000
CY2022Q4 mgtx Accrued Expenses Incurred In Connection With Fixed Assets
AccruedExpensesIncurredInConnectionWithFixedAssets
3093000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
260000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
932000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24889000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
39818000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6858409
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.03
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1552340
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
97874
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.48
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8312875
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M1D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5295277
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M21D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1996
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1983
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3500000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4200000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4200000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4200000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
9700000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
11000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.19
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7271000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7303000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13703000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14881000
mgtx Excess Tax Benefit From Share Based Compensation Operating Activities1
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
0
mgtx Excess Tax Benefit From Share Based Compensation Operating Activities1
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities1
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2600000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
282000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
275000
CY2023Q2 mgtx Finance Lease Cost
FinanceLeaseCost
282000
CY2022Q2 mgtx Finance Lease Cost
FinanceLeaseCost
275000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1370000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1341000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
38000
CY2023Q2 us-gaap Lease Cost
LeaseCost
1691000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1654000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
563000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
568000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000
mgtx Finance Lease Cost
FinanceLeaseCost
563000
mgtx Finance Lease Cost
FinanceLeaseCost
569000
us-gaap Operating Lease Cost
OperatingLeaseCost
2731000
us-gaap Operating Lease Cost
OperatingLeaseCost
2675000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
78000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
76000
us-gaap Lease Cost
LeaseCost
3372000
us-gaap Lease Cost
LeaseCost
3320000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18693000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20109000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
19634000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21215000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24626000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
24718000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M6D
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P175Y3M18D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P175Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q2 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1442000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1365000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
8000
us-gaap Operating Lease Payments
OperatingLeasePayments
2826000
us-gaap Operating Lease Payments
OperatingLeasePayments
2735000
mgtx Finance Lease Payments
FinanceLeasePayments
1000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1793000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2852000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5549000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5501000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5244000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1903000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
2967000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
24016000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4382000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
19634000
CY2023Q2 mgtx Number Of New Material Commitments
NumberOfNewMaterialCommitments
0

Files In Submission

Name View Source Status
0001558370-23-014416-index-headers.html Edgar Link pending
0001558370-23-014416-index.html Edgar Link pending
0001558370-23-014416.txt Edgar Link pending
0001558370-23-014416-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgtx-20230630.xsd Edgar Link pending
mgtx-20230630x10q.htm Edgar Link pending
mgtx-20230630xex10d3.htm Edgar Link pending
mgtx-20230630xex10d4.htm Edgar Link pending
mgtx-20230630xex31d1.htm Edgar Link pending
mgtx-20230630xex31d2.htm Edgar Link pending
mgtx-20230630xex32d1.htm Edgar Link pending
mgtx-20230630xex32d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mgtx-20230630_cal.xml Edgar Link unprocessable
mgtx-20230630_def.xml Edgar Link unprocessable
mgtx-20230630x10q_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mgtx-20230630_pre.xml Edgar Link unprocessable
mgtx-20230630_lab.xml Edgar Link unprocessable